news
Global API market to value $300 billion by 2030
Researchers anticipate the growth of the aging population and rising investment in biologic drugs to promote the expansion of the global active pharmaceutical ingredient (API) market.
List view / Grid view
Teva Pharmaceutical Industries Ltd
news
Connected drug delivery devices market to grow to $4bn by 2028
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
news
Six pharma companies reported to be under investigation for opioid shipments
US prosecutors have handed subpoenas to six pharmaceutical companies and distributors for their role in the opioid crisis, as reported.
news
Teva to supply treatment in settlement agreement on Track 1 opioid case
Teva has agreed to supply opioid medication and make a cash payment in a settlement agreement that removes it from the Track 1 opioid litigation.
news
Drugmakers may use Purdue’s bankruptcy to settle opioid suits
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
article
Top five generic drug makers
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
news
$85 million settlement agreed for opioid case in Oklahoma
Teva has agreed to pay Oklahoma, resolving allegations that illegal marketing of its medication contributed to the state’s opioid epidemic.
news
Teva supports IVF Worldwide to improve knowledge of fertility preservation protocols
10 March 2016 | By Victoria White
Teva is to support IVF-Worldwide with a research grant to improve knowledge of fertility preservation protocols for women diagnosed with cancer...
article
European Pharmaceutical Review’s top 10 stories from 2015
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
news
Teva acquires Mexican company Rimsa for $2.3b
2 October 2015 | By Victoria White
Through the Rimsa acquisition, Teva will become a leading pharmaceutical company in the second largest market in Latin America...
news
Teva files MAA for asthma treatment reslizumab
28 July 2015 | By Victoria White
Teva has successfully filed a MAA with the EMA for reslizumab -a humanised anti-IL-5 monoclonal antibody for the treatment of inadequately controlled asthma...
news
Teva withdraws proposal to acquire Mylan
28 July 2015 | By Victoria White
Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan...
news
Allergan to acquire Naurex; divests generics business to Teva
27 July 2015 | By Victoria White
Allergan followed an announcement it made yesterday about its acquisition of Naurex with news today that it is to divest its generics business to Teva...
news
Teva first to receive approval and launch generic Axert tablets in the US
9 July 2015 | By Victoria White
Teva has launched generic Axert® (almotriptan malate) tablets in the US for the treatment of migraine attacks in adults and adolescents...
news
Teva’s DuoResp Spiromax wins silver at the 2015 Medical Design Excellence Awards
2 July 2015 | By Victoria White
Teva’s DuoResp Spiromax inhaler for patients with asthma and COPD has won silver at the 2015 Medical Design Excellence Awards (MDEA)...